From: Gary Maier <S=Maier%C=US%G=Gary%O=ELFSANOFI%OU1=PA01%ELF21@mcimail.com>
Subject: NONMEM and identification of drug-drug interactions
Date: 16 Dec 1997 14:58:00 -0500
Hello,
Recently I attended a meeting where two somewhat different viewpoints on the use of population PK in assessing drug-drug interactions were presented. As I am faced with this situation at Sanofi, I was wondering if you could take the time and let me and the user community know what experience you have had in using population PK to identify possible drug-drug interactions and describe the limiting situations you may have experienced. Are there any circumstances under which you would advocate the use of population PK to test hypothesized interactions or would you resort to more traditional designs
Under what circumstances did you for example encounter either false positive or negative results
thanks in advance for your help in this matter,
Gary Maier
Sanofi
****
From: Janet.Wade@mpa.se
Subject: Drug Interactions
Date: 17 Dec 1997 07:02:31 -0500
Hello there!
Whilst this may not directly deal with all the points Gary Maier raised in his e-mail with respect to drug interactions and the population approach, maybe the following short summary of what has happened in the last two years within the European regulatory environment will be useful.
The inclusion of population analyses in the documentation submitted is increasing, and almost doubled in 1997 versus 1996. By far, the most frequent use made of the results of the population analyses submitted is in the area of drug interactions. The population analysis results have been used both to support drug label claims of the lack of interactions, and to quantify interactions (with dosage adjustments if needed). Indeed, the great use to which the population approach has been put to in this respect prompted the inclusion of a section addressing the use of the approach in detecting drug interactions in the new CPMP guideline for drug interactions (and, I think, which should be adopted at the CPMP meeting that is ongoing this week). I have enclosed a copy of the latest version that I have of that text, at the end of this letter.
With regard to false positives, we have been applying a somewhat arbitrary rule of thumb that if an interaction is detected (on clearance for example) but its magnitude is less that the estimated intersubject variability in clearance, then that is not included in the drug label. Obviously this depends on where the interaction is on the concentration response curve, but we are often in ignorance of that so we do the best we can. This arbitrary rule of thumb has also not been universally applied, sometimes interactions that are of a smaller magnitude have been included in the drug label in the interests of maintaining European harmony.
With regard to false negatives, we always like/want to see the confidence interval associated with the lack of effect, so as to have some idea of the reliability of the results. I mentioned this fact at a meeting I attended earlier this month and was told by Leon Aarons that we should also be interested in the confidence interval of the confidence interval, maybe someone other than me can address this point! Going back to false negatives, we also look at how many subjects are taking the potentially interacting drug, although what is deemed a sufficient number is currently judged on a case by case basis (sorry for that piece of regulatory rhetoric!).
What follows next is the section dealing with the population approach in the new CPMP guideline on drug interactions.
Janet R. Wade
Swedish Medical Products Agency
Population Studies
It is often valuable to include a population approach in Phase II/III clinical trials to screen for pharmacokinetic drug interactions. Valuable additional information is then obtained from studies that are performed for other reasons. It is, however, important to remember that in the context of the population approach, these studies may not randomised and can therefore be subject to the usual bias of observational studies. The outcome should mainly be used as hypothesis-generating and the best use of this approach can probably be made to highlight unsuspected interactions and possibly to confirm absence of suspected interactions. The successful use of such an approach is highly dependent upon the protocol inclusion criteria so that:
1. Sufficient numbers of patients taking the potentially interacting drug exist (to avoid falsely not finding an interaction).
2. Information should be available as to when the interacting drug was taken, and should be within a reasonable time frame with respect to when the test drug was administered.
In order to avoid drawing incorrect conclusions, in particular false negative conclusions, certain aspects of analysis need special attention, because the statistical models and computational procedures used to analyse population pharmacokinetic studies can be particularly complex. It is important to ensure that the particular models chosen and procedures used are reliable, and are appropriate for the statistical distribution of the data. In addition, the influence of potential confounding factors, such as age or other demographic or pathophysiological characteristics, on the results and conclusions should be checked, bearing in mind the potential lack of randomisation and the possibility for bias.
A confidence interval associated with the estimate of the interaction should be presented. This is particularly important if no significant interaction is detected in order to permit an assessment of the degree of interaction potentially excluded.
****
From: Mats Karlsson <mats.karlsson@biof.uu.se>
Subject: Re: NONMEM and identification of drug-drug interactions
Date: 17 Dec 1997 10:48:52 -0500
Gary,
I made a presentation on the topic at a DIA meeting earlier this year. Below I've enclosed a copy of it. It is only bullet points, but maybe you'll find something useful.
Best regards,
Mats Karlsson
****
From: "BRUNO, Rene" <Rene.BRUNO@rp-rorer.fr>
Subject: NONMEM and drug-drug interaction
Date: 17 Dec 1997 11:05:54 -0500
Hi everybody, I have one experience of a negative result and a few comments:
We have prospectively integrated pop PK/PD approach in the development of docetaxel (TaxotereR), an anticancer agent and came up with a data base of 577 patients from 22 Phase II studies in the registration dossier (based on Phase II studies only). We identified covariates predictive of PK variability and demonstrated that PK variability was a significant predictor of several safety endpoints. Docetaxel is a CYP3A substrate. In our data base no patients were coadministered known inhibitors of CYP3A and we did not look at drug-drug interactions in the main analysis, mainly because the dosage regimen of co-administered drugs (and especially the actual time of intake of the co-administered drug relative to the time of docetaxel administration) was not well documented.
One side-effect of docetaxel treatment is fluid retention. During the course of clinical studies several premedication regimens were tested to prevent this problem. A five-day dexamethasone premedication (8 mg po b.i.d. starting the day before docetaxel infusion) significantly delayed the onset and reduced the severity of docetaxel induced fluid retention. However, the concern was raised by a regulatory agency that the effect of dexamethasone could be due to an induction of docetaxel CL (and the resultant decrease of drug exposure) via CYP3A induction rather than by a direct effect of dexamethasone. This question was of importance since it conditioned the approvability of the premedication regimen. A retrospective look at the population PK data base indicated that 82 patients received dexamethasone with various schedules including 25 treated with the recommended 5 day schedule. We tested the effect of dexamethasone premedication on docetaxel CL using the population PK model, and found none. In the absence of these data, a specific clinical trial would have been required to assess docetaxel PK in patients receiving the recommended dexamethasone premedication.
I think, one major limitation is the documentation of dosage regimen of coadministered drugs. If the analysis is planned in advance however, the dosage regimen of the drug of interest can be documented and may be subjected to some control without jeopardizing the clinical study objectives.
With respect to Janet's point regarding false negatives. I haven't look at back to my files regarding the dexamethasone analysis but I think that when you test an effect when there is none (say change in CL in patients having received a given drug), the parameter estimate related to this effect is typically going to be very small (say less than 1% of 0.5% change in clearance) with a large confidence interval. Am I wrong ?
Rene Bruno
Rhone-Poulenc Rorer
Reference : Bruno R. Integration of Population PK/PD in the Clinical Development and the Registration Dossier of Docetaxel. In: L. Aarons et al. editors. The Population Approach: Measuring and managing variability in response, concentration and dose. European Commission, Luxembourg, 253-262, 1997.
****
From: "Dr Ziad Hussein" <ziadh@fs1.pa.man.ac.uk>
Subject: Re: NONMEM and identification of drug-drug interactions
Date: 17 Dec 1997 12:51:48 -0500
I was involved in the population PK of 2 different drugs where we looked at drug-drug interaction.
For lamotrigine, we examined any interaction with oral contraceptives. The outcome was negative- not interaction [Z. Hussein & J. Posner. Br J Clin Pharmacol 1997; 43:457-465].
For atovaquone, we examined any possible interaction with proguanil (chloroguanide), pyrimethamine and tetracycline. Also in this case there was no drug-drug interaction [Hussein et al. Clin Pharmacol Ther 1997; 61:518-30].
Also, reference is made to the talk about this topic by Professor Tom Ludden,
University of Nebraska, at the last COST meeting in Geneva. A book with all oral and poster presentations was sent to all participants.
Dr Ziad Hussein
Centre for Applied Pharmacokinetic Research
The University of Manchester
Oxford Road
Manchester M13 9PL
United Kingdom
****
From: "Gibiansky, Ekaterina" <Katyag@mocr.oapi.com>
Subject: RE: NONMEM and identification of drug-drug interactions
Date: 17 Dec 1997 14:48:03 -0500
Gary,
Recently I was involved in the population PK of cilostazol where we looked at drug-drug interactions. We screened all the concomitant medications used by more than 25 patients (5% of all the patients). Of 21 different drugs, diltiazem showed to increase cilostazol exposure [Gibiansky et al. Pharm. Res. 1997 14(11):515]. Retrospectively, it made sense: diltiazem was a CYP3A4 inhibitor. Cilostazol is metabolized via 3A4, and it was known that erythromycin increased cilostazol exposure. Initially, the idea was to look at frequently coadministered drugs, and separately to look at inhibitors and stimulators of certain isozymes grouped together. But for most of drugs we were not able to find that information.
Katya Gibiansky
Otsuka America Pharmaceuticals, Inc.
2440 Research Blvd, Rockville, MD 20850 USA
E-mail: katyag@mocr.oapi.com
Phone: (301)-527-4911
Fax: (301)-721-7511
****
From: Mats Karlsson <mats.karlsson@biof.uu.se>
Subject: RE: NONMEM and identification of drug-drug interactions
Date: 19 Dec 1997 05:21:10 -0500
Katya,
I couldn't find your earlier message, so the answer has to be a general one. If you found that drugs in a therapeutic area dont interact with your drug, it seems reasonable to claim that the action of those agents (whether it is diuresis, lowering of gastric pH or something else) does not seem to influence the PK of your drug. To make the claim that there is no PK interaction, is harder, especially if the group of drugs is heterogeneous with respect to binding, metabolism and transport mechanisms. However, I think that a statement that says: no influence on the PK of X was found when concomitant medication was grouped as beta-blockers (n=88), NSAIDS (n=33), etc, would still be useful. It conveys some reassurance and for those knowledgeable in pharmacokinetics, they would be able to do the distinction that the information may be more relevant for relatively homogeneous groups.
Merry Christmas,
Mats
PS For those of you that asked for the presentation in a different format, I will send it when I get back to work (Im working from home now).
****
From: "Dr Ziad Hussein" <ziadh@fs1.pa.man.ac.uk>
Subject: RE: NONMEM and identification of drug-drug interactions
Date: 19 Dec 1997 07:17:47 -0500
The approach of grouping drugs by class (e.g., beta blockers) when looking at drug-drug interaction in a population PK/PD analysis is becoming a common practice by those of us who perform such analysis.
The reason behind the grouping is simply that there might be few drugs in a class and the number of patients receiving each drug is too small to examine the effect of each drug individually. Although looking at drug-drug interaction by class of drugs is a better approach than looking at nothing we have to be careful about it. There might be a drug in the class that might significantly interact (statistically and/or clinically) with the drug of interest. However, because the number of patients receiving this particular drug was small it was pooled/grouped with others from the same class and consequently the effect will diluted.
Regards,
Dr Ziad Hussein
Centre for Applied Pharmacokinetic Research
School of Pharmacy & Pharmaceutical Sciences
The University of Manchester
Oxford Road
Manchester M13 9PL
United Kingdom
****
From: Cornelia Weber 41 61 68 88017 <CORNELIA.WEBER@roche.com>
Subject: Re: Drug Interactions
Date: 19 Dec 1997 08:30:31 -0500
I am planning to include the evaluation of drug-drug-interactions in the population PK analysis of two phase III trials. I would like to group concomitant medications into groups such as e.g. CYP3A4 inhibitors, CYP2C9 substrates, CYP2C9 inducers etc. based on the fact that "my" drug of interest is a CYP3A4 and CYP2C9 substrate. Does anybody has experience with such an approach? Wouldn't that make more sense from a scientific point of view than using classes like diuretics or Ca-antagonists? It might well be that the majority of drugs in such a class has the same elimination pathway. But there are cases where one or more drugs in such a class have an elimination pathway which differs from that of the others? If the mentionned approach is used would you still propose to also investigate the data using the other approach of coding drugs into groups in parallel?
Thanks for your answers in advance.
Conni Weber
Clinical Pharmacology
Hoffmann-La Roche Base, Switzerland
****
From: Mats Karlsson <mats.karlsson@biof.uu.se>
Subject: Re: Drug Interactions
Date: 19 Dec 1997 09:17:50 -0500
Cornelia and other nmusers
To group by therapeutic area and to group by suspected mechanism of interaction are by no means mutuallly exclusive. I think that the latter in general is the more interesting, but it requires classification of a large number of drugs into classes of e.g. CYP3A4 inhibitors, drugs actively secreted and drugs that are substrates for p-gp. I'm sure that many would be grateful if those that have compiled such listings made them available to others. Maybe the Palo Alto site would be a suitable stoaring place.
Mats Karlsson
****
From: "Gibiansky, Ekaterina" <Katyag@mocr.oapi.com>
Subject: RE: NONMEM and identification of drug-drug interactions
Date: 19 Dec 1997 10:07:34 -0500
Mats,
I had approximately the same arguments as you do. Counter arguments were that since not all beta blockers or NSAIDs were used concomitantly in the trials we can not claim no interaction with the whole class. As soon as it comes to listing all those that were used (with only few of each) the whole idea loses any sense.
Happy Holidays
Katya
****
From: Robert Shore 301-443-3510 FAX 301-443-9282 <SHORER@cder.fda.gov>
Subject: Re: Drug Interactions
Date: 19 Dec 1997 10:34:31 -0500
Yet another point for discussion (and pardon me if it has already been brought up):
Exposure to 'the other' drug is important. That is, if there is a list of concomitant medications which are going to be lumped together in groups (however this is done: class, CYP activity), there needs to be some measure of exposure to these others medications. Often, from clinical trials, lists of concomitant medications include patients that took one doseof these 'other medications' once as well as patients that took 'other medications' chronically. And there may not be PK data for those concomitant medications. If it is a specific drug-drug interaction study in which all subjects received the same doses of all medications, that may be different. But if this difference in exposure to the concomitant medication(s) is not taken into account, how reliable is the analysis? What does 'no interaction' from such an analysis mean?
The opinions expressed in this Email are mine alone and do not represent the opinion of the FDA.
Rob Shore
****
From: JWALD@quintiles.com (Jeff Wald)
Subject: Re: Drug Interactions
Date: 19 Dec 1997 15:38:59 -0500
Conni - I agree, it makes more sense to look at categories based on functional similarities.
It has been my understanding that therapeutic class categorizations of drugs is more an issue of convenience than based on any scientific rationale. Typically, drugs are coded by class in the scientific database for the purposes of the safety evaluation. To maintain consistency with the safety evaluation, and because it is already in the database, therapeutic class categories have been used for population PK/PD analyses. This may be the best way to handle PD analyses (ie, to find drugs that have a pure PD interaction). However, PK analyses may require their own coding methods. There are many different types of coding schemes that could be envisioned to answer PK questions such as specific CYP inhibitors or inducers, drugs that are highly bound to plasma proteins, etc... Perhaps the community needs a concomitant coding dictionary that includes meaningful categories for population PK analyses.
Regards,
Jeff Wald
_____________________________________________________________
Quintiles, Incorporated
Post Office Box 13979
Research Triangle Park, North Carolina
27709-3979
Phone 919-941-7245
Fax 919-941-0493